Cargando…
Epidermolysis bullosa acquisita as an adverse effect from rituximab therapy: A case report
RATIONALE: Rituximab is a monoclonal antibody directed against B cells and is a first-line agent for the treatment of B cell lymphoma and a second-line agent for the treatment of idiopathic thrombocytopenic purpura (ITP). It has also been used for the treatment of several other autoimmune diseases....
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7717850/ https://www.ncbi.nlm.nih.gov/pubmed/33285756 http://dx.doi.org/10.1097/MD.0000000000023496 |